Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person’s bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures. Osteoporosis is often referred to as a “silent” disease because the loss of bone occurs progressively and often there are no symptoms until the first fracture occurs (SCOPE, 2021). The bones become so weak and brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture (Mayo Clinic, 2024). Around the world, one in three women and one in five men are at risk of an osteoporotic fracture (SCOPE, 2021). The morbidity and mortality associated with osteoporotic fractures make osteoporosis a global health burden second only to cardiovascular disease (Kanis et al., 1997; Pisani et al., 2016). As the world’s population ages, the global burden of the disease is expected to increase.
In the 7MM, the total prevalent cases of osteoporosis will increase from 51,169,521 cases in 2023 to 58,050,255 cases in 2033, at an annual growth rate (AGR) of 1.34%. In the 7MM, the diagnosed prevalent cases of osteoporosis will increase from 20,291,551 cases in 2023 to 22,570,292 cases in 2033, at an AGR of 1.12%. The analyst forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of osteoporosis during the forecast period.
In the 7MM, the total prevalent cases of osteoporosis will increase from 51,169,521 cases in 2023 to 58,050,255 cases in 2033, at an annual growth rate (AGR) of 1.34%. In the 7MM, the diagnosed prevalent cases of osteoporosis will increase from 20,291,551 cases in 2023 to 22,570,292 cases in 2033, at an AGR of 1.12%. The analyst forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of osteoporosis during the forecast period.
Scope
- This report provides an overview of the risk factors, comorbidities, and global and historical trends for osteoporosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of osteoporosis, and total and diagnosed prevalent cases of primary osteoporosis, segmented by sex and age (ages 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) in these markets. In addition, this report provides a 10-year epidemiological forecast for the total and diagnosed prevalent cases of secondary osteoporosis, and total and diagnosed prevalent cases of osteopenia, segmented by sex. The report also includes the total and diagnosed prevalent cases of type 1 (postmenopausal) osteoporosis, the total and diagnosed prevalent cases of type 2 (age-associated/senile) osteoporosis, and total and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use.
- To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, The analyst epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. The analyst epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market research. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.
Reasons to Buy
The Osteoporosis epidemiology series will allow you to :
- Develop business strategies by understanding the trends shaping and driving the global MM market.
- Quantify patient populations in the global Osteoporosis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Osteoporosis therapeutics in each of the markets covered.
Table of Contents
1 Osteoporosis: Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
